Welcome to Mysimba®

Please click below for online meeting : The Collision of Two Pandemics: Obesity and COVID-19 with Dr Michael Crotty.

Join Dr Michael Crotty as he discusses the management of patients living with Obesity. During the course of his presentation (divided into ten discrete sections) , Dr Crotty reviews the pathophysiology of Obesity as a chronic disease and discusses the evidence-based medical treatments for chronic management of Obesity.


Latest Thinking in Weight Management


Mysimba® Indication


Mysimba® Dosing Information


Adverse Event Reporting


Further Information

IE-MYS-148 | Date of preparation: November 2020

Mysimba®is subject to additional monitoring. To report an adverse event or a product complaint about Mysimba®, please contact: HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517; Website: www.hpra.ie; e-mail: medsafety@hpra.ie Adverse events should also be reported to Adverse events should also be reported to Nalpropion Pharmaceuticals LLC®: 1-800- 902-210 or Mysimba@druginfo.com.

For all other queries, please contact our Irish office at Tel: +353 (0)1 2057760, Fax: +353 (0)1 2698919 or irishoffice@consilienthealth.com

The information on this website is intended for healthcare professionals registered in the Republic of Ireland only.

Mysimba® is a registered trademark of Nalpropion Pharmaceuticals LLC

© 2020 Nalpropion Pharmaceuticals LLC

Other trademarks, registered or otherwise, are the property of their respective owners.